Clinical characteristics of CNS metastases from primary gynecologic cancers☆
Sign Up to like & getrecommendations! Published in 2019 at "Gynecologic Oncology Reports"
DOI: 10.1016/j.gore.2019.100518
Abstract: Highlights • Most common symptoms for patients with CNS metastases are headaches and ataxia.• Multiple foci are more common than solitary lesions on initial brain imaging.• The frontal lobe is most likely to be involved.•… read more here.
Keywords: characteristics cns; gynecologic cancers; primary gynecologic; cns metastases ... See more keywords
Application of clinical trial inclusion criteria to clinical practice patients to quantify the burden of CNS metastases on health-related quality of life and healthcare resource use in patients with NSCLC.
Sign Up to like & getrecommendations! Published in 2020 at "Lung cancer"
DOI: 10.1016/j.lungcan.2020.09.007
Abstract: OBJECTIVES Quantify the burden of central nervous system (CNS) metastases on health-related quality of life (HRQoL) and healthcare resource use (HRU) in patients with advanced non-small-cell lung cancer (NSCLC) from a prospective European study in… read more here.
Keywords: clinical trial; cns metastases; clinical practice; cns ... See more keywords
Impact of breast cancer molecular subtypes on the incidence, kinetics and prognosis of central nervous system metastases in a large multicentre real-life cohort
Sign Up to like & getrecommendations! Published in 2019 at "British Journal of Cancer"
DOI: 10.1038/s41416-019-0619-y
Abstract: Metastatic breast cancer (MBC) behaviour differs depending on hormone receptors (HR) and human epidermal growth factor receptor (HER2) statuses. The kinetics of central nervous system (CNS) metastases (CNS metastasis-free survival, CNSM-FS) and subsequent patient’s prognosis… read more here.
Keywords: cns metastases; nervous system; central nervous; breast cancer ... See more keywords
Effectiveness of ALK inhibitors in treatment of CNS metastases in NSCLC patients.
Sign Up to like & getrecommendations! Published in 2023 at "Annals of medicine"
DOI: 10.1080/07853890.2023.2187077
Abstract: Metastases to the central nervous system (CNS) in patients with non-small cell lung cancer constitute an extremely difficult clinical problem, and their occurrence is associated with a poor prognosis. Due to the existence of the… read more here.
Keywords: alk inhibitors; nsclc patients; inhibitors treatment; cns metastases ... See more keywords
Osimertinib in epidermal growth factor receptor (EGFR) T790M advanced non-small cell lung cancer (NSCLC): Analysis of patients with central nervous system (CNS) metastases in a real-world study (ASTRIS)
Sign Up to like & getrecommendations! Published in 2019 at "Annals of Oncology"
DOI: 10.1093/annonc/mdz260.043
Abstract: Abstract Background Approximately 20%–30% of patients (pts) with EGFR mutation-positive NSCLC present with CNS metastases at the time of diagnosis of advanced disease. CNS metastases are associated with a poor prognosis. Osimertinib is a third-generation,… read more here.
Keywords: research; cns metastases; astrazeneca; cns ... See more keywords
CTNI-04. ACTIVITY OF LAROTRECTINIB IN TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES
Sign Up to like & getrecommendations! Published in 2020 at "Neuro-oncology"
DOI: 10.1093/neuonc/noaa215.171
Abstract: NTRK gene fusions occur in a range of tumor types, including those with CNS metastases. Larotrectinib, a highly selective FDA- and EMA- approved TRK inhibitor, demonstrated an objective response rate (ORR) of 79% across various… read more here.
Keywords: response; cns metastases; fusion cancer; cancer ... See more keywords
Clinical characteristics of CNS metastases of different breast cancer subtypes - Results from a cohort study
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs16-p1-12-09
Abstract: Clinical characteristics of CNS metastases of different breast cancer subtypes - Results from a cohort study read more here.
Keywords: characteristics cns; different breast; cns metastases; metastases different ... See more keywords
Abstract P2-20-01: Impact of neratinib on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer (MBC): Findings from the NALA, NEfERT-T, and TBCRC 022 trials
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs19-p2-20-01
Abstract: Background: The development of metastatic disease in the CNS presents a considerable challenge in the management of patients with MBC as a result of the lack of evidence-based treatment options currently available. Up to 50%… read more here.
Keywords: cns; progression; cancer; tbcrc 022 ... See more keywords
A phase II study of atezolizumab (Atezo) combined with pertuzumab (P) and high-dose trastuzumab (H) for the treatment of central nervous system (CNS) metastases in patients with Her2-positive (HER2+) metastatic breast cancer (MBC).
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2018.36.15_suppl.tps1100
Abstract: TPS1100Background: There is no clear standard of care to address the management of refractory CNS metastases in HER2+ MBC. The ongoing study (NCT03417544) is evaluating the efficacy of the combination of Atezo with P and… read more here.
Keywords: metastases patients; cns metastases; high dose; treatment ... See more keywords
Elemene treatment for NSCLC with multiple CNS metastases: a case report and literature review
Sign Up to like & getrecommendations! Published in 2018 at "OncoTargets and therapy"
DOI: 10.2147/ott.s160970
Abstract: CNS metastases are common in patients with non-small-cell lung cancer (NSCLC) and is associated with poor prognosis. In NSCLC patients with EGFR mutations, and ALK fusion oncogene, chemotherapy is ineffective; however, targeted and pulse therapies… read more here.
Keywords: cns metastases; elemene treatment; case; treatment nsclc ... See more keywords
Efficacy of PD-1 or PD-L1 inhibitors and central nervous system metastases in advanced cancer: a meta-analysis.
Sign Up to like & getrecommendations! Published in 2021 at "Current cancer drug targets"
DOI: 10.2174/1568009621666210601111811
Abstract: BACKGROUND Little is known about the efficacy of programmed cell death protein-1 (PD-1) or programmed cell death-ligand 1 (PD-L1) inhibitors in patients with central nervous system (CNS) metastases. OBJECTIVE Assess the difference in efficacy of… read more here.
Keywords: cns metastases; central nervous; efficacy; patients cns ... See more keywords